

Erica L Goodrich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6482669/publications.pdf>

Version: 2024-02-01

35
papers

4,011
citations

430754

18
h-index

377752

34
g-index

39
all docs

39
docs citations

39
times ranked

5427
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 895-902.	0.8	18
2	Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. <i>Diabetes Care</i> , 2022, 45, 938-946.	4.3	20
3	Epidemiology and Management of STâ€‘segmentâ€‘Elevation Myocardial Infarction in Patients With COVIDâ€‘19: A Report From the American Heart Association COVIDâ€‘19 Cardiovascular Disease Registry. <i>Journal of the American Heart Association</i> , 2022, 11, e024451.	1.6	6
4	Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. <i>Circulation</i> , 2022, 145, 1581-1591.	1.6	13
5	Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodiumâ€‘glucose coâ€‘transporter 2 inhibitor therapy in <sc>DECLAREâ€‘TIMI</sc> 58. <i>European Journal of Heart Failure</i> , 2021, 23, 1026-1036.	2.9	35
6	Cardiorenal outcomes with dapagliflozin by baseline glucoseâ€‘lowering agents: Post hoc analyses from <sc>DECLAREâ€‘TIMI</sc> 58. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 29-38.	2.2	28
7	Efficacy and safety of vorapaxar for secondary prevention in low body weight in patients with atherosclerosis: analyses from the TRA 2â€‘P-TIMI 50 Trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 190-199.	0.4	5
8	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. <i>Diabetes Care</i> , 2021, 44, 1159-1167.	4.3	25
9	Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2â€‘Pâ€‘TIMI 50. <i>Journal of the American Heart Association</i> , 2021, 10, e018673.	1.6	7
10	MEDIATION ANALYSIS FOR DAPAGLIFLOZIN AND THE REDUCTION IN HOSPITALIZATION FOR HEART FAILURE IN DECLARE-TIMI 58. <i>Journal of the American College of Cardiology</i> , 2021, 77, 869.	1.2	3
11	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. <i>Diabetes Care</i> , 2021, 44, 1805-1815.	4.3	49
12	Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes. <i>JAMA Cardiology</i> , 2021, 6, 801.	3.0	26
13	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. <i>Diabetes Care</i> , 2021, 44, 2573-2581.	4.3	13
14	Efficacy and Safety of Vorapaxar by Intensity of Background Lipidâ€‘Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2Pâ€‘TIMI 50 Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e021412.	1.6	1
15	Epidemiology of Cardiogenic Shock in Hospitalized Adults With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry. <i>Circulation: Heart Failure</i> , 2021, 14, CIRCHEARTFAILURE121008477.	1.6	12
16	Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLAREâ€‘TIMI 58 Study. <i>Diabetes Care</i> , 2020, 43, 468-475.	4.3	72
17	Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. <i>JAMA Cardiology</i> , 2020, 5, 1255.	3.0	27
18	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. <i>Circulation</i> , 2020, 142, 734-747.	1.6	44

#	ARTICLE	IF	CITATIONS
19	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 606-617.	5.5	482
20	Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2 ^Â P-TIMI 50 trial. <i>Vascular Medicine</i> , 2019, 24, 159-161.	0.8	3
21	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 139, 2022-2031.	1.6	523
22	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet</i> , 2019, 393, 31-39.	6.3	1,958
23	Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 353-360.	1.0	7
24	244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial. <i>Diabetes</i> , 2019, 68, 244-OR.	0.3	11
25	Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 830-838.	0.8	20
26	Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis. <i>Circulation</i> , 2018, 137, 684-692.	1.6	22
27	Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2018, 7, e009077.	1.6	35
28	Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	8
29	Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in) Tj ETQq1 1 0:Z84314 rgBT /Ove		
30	Short Sleep Duration, Obstructive Sleep Apnea, Shiftwork, and the Risk of Adverse Cardiovascular Events in Patients After an Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	46
31	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2719-2728.	1.2	303
32	Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction. <i>Circulation</i> , 2016, 134, 861-871.	1.6	40
33	Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2157-2164.	1.1	39
34	METABOLIC SYNDROME AND THE RISK OF ADVERSE CARDIOVASCULAR EVENTS AFTER AN ACUTE CORONARY SYNDROME: INSIGHTS FROM SOLID-TIMI 52 TRIAL. <i>Journal of the American College of Cardiology</i> , 2016, 67, 448.	1.2	0
35	Emotion displays in media: a comparison between American, Romanian, and Turkish children's storybooks. <i>Frontiers in Psychology</i> , 2014, 5, 600.	1.1	13